

ICoLA 2019

The 8th International Congress on Lipid &Atherosclerosis(ICoLA)
The 58th Conference of the Korean Society of Lipid & Atherosclerosis (KSoLA)

September 5(Thu.) ~ 7(Sat.), 2019, Conrad Hotel Seoul, Republic of Korea

Lecture Abstract or Synopsis for publication

Current Status of Drugs for Raising HDL-cholesterol

SUNG HEE CHOI

Endocrinology & Metabolism, Internal Medicine, Seoul National University, College of Medicine

shchoimd@gmail.com

Abstract

Many attempts have been made to enhance HDL levels based on the belief that raising HDL-cholesterol would have beneficial effect on decreasing atherosclerotic cardiovascular diseases. However, there seems a big gap between ideal theory and realtiy regarding to HDL-cholesterol and many drug trials could not result in fancy results.

In this talk, I want to discuss the past and current drugs targeting HDL-cholesterol, its mechanisms and results of CVD outcome trials.

Keywords

HDL-cholesterol, Apo A1, CETP inhibitor

Secretariat People & Value, Inc., #1001 Botatic Park Tower, 161-17 Magokjungang-ro, Gangseo-gu, Seoul 07788, Republic of Korea Tel: +82-2-2135-3617 Fax: +82-2-564-2123 E-mail: secretariat@icola.org